Pegylated Recombinant Human Arginase I

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pegylated Recombinant Human Arginase I
DrugBank Accession Number
DB16282
Background

Pegylated Recombinant Human Arginase I is under investigation in clinical trial NCT03455140 (A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)).

Type
Biotech
Groups
Investigational
Synonyms
  • Pegylated recombinant human arginase i bct-100
External IDs
  • BCT-100
  • RH-ARG1-PEG-5,000 MW

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmbroxolThe risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Bupivacaine.
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
S3HC6XX81X
CAS number
1433787-75-7

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHepatocellular Carcinoma2
2Unknown StatusTreatmentAcute Myeloid Leukemia1
1CompletedTreatmentAdenocarcinoma of Prostate / Melanoma1
1CompletedTreatmentHepatocellular Carcinoma / Neoplasm1
1TerminatedTreatmentLeukemias / Lymphoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 15, 2020 18:17 / Updated at December 20, 2020 03:40